Supported by science

Omega-3 fatty acids EPA and DHA are investigated in clinical science for wide range of health conditions. Currently major therapeutic application of EPA and DHA is in CVD and refers to lowering plasma triglyceride levels.  Backed by extensive scientific evidence, EPA and DHA provide vital support to heart health in pharmaceutical applications, lowering plasma triglycerides levels, decreasing resting heart rate, blood pressure and inflammation, and improving vascular function.

Clinical trials referring to DHA and EPA cover such conditions as rheumatoid arthritis, osteoporosis, stroke, traumatic brain injury, cognitive decline, Alzheimer’s disease, depression, attention deficit/hyperactivity disorder, macular degeneration, asthma, inflammatory bowel disease, colon/breast/prostate cancer, skin disorders, sarcopenia, post-surgical recovery and others.

Contact us to find out more about our broad spectrum of EPA and DHA ingredients. 

October 10, 2018
The Evolving Role of Vitamins: DSM Presents at Nicholas Hall’s 5th Asia-Pacific Consumer Healthcare Conference READ MORE
July 25, 2018
Visit us at CPhI 2018 to discover the rapidly evolving role of vitamins and lipids in disease treatment READ MORE
May 1, 2018
From Supplement to Treatment: DSM Presents at Nicholas Hall’s 29th OTC Insights Conference READ MORE
April 27, 2018
Back to Basics: The Impact of B-Vitamins on Low Back Pain READ MORE
April 23, 2018
To Your Health: The Growing Importance of Clinically Relevant Drug-Nutrient Interactions READ MORE
March 19, 2018
Download our 2018 Pharmaceutical Solutions Brochure READ MORE